RNA-based Drug Formulation Development Service
Overview
The therapeutic landscape has been radically transformed by the emergence of RNA-based modalities, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs). Despite their profound potential to "drug the undruggable," these molecules face significant physiological hurdles: rapid enzymatic degradation, poor cellular uptake, and inherent instability. CD BioGlyco addresses these critical bottlenecks through our RNA-based drug formulation development service. By combining advanced lipid nanoparticle (LNP) engineering with proprietary stabilization techniques, we ensure that your fragile nucleic acid payloads are protected, targeted, and delivered with maximum efficiency. Our multidisciplinary approach integrates biophysics, material science, and pharmacology to move your RNA candidate from the bench to the clinic with unprecedented speed and precision.
Core Technologies
To overcome the delivery barriers of RNA, we utilize a state-of-the-art technological ecosystem:
- Ionizable Lipid Library
We maintain a diverse library of proprietary lipids designed for high endosomal escape and low immunogenicity, allowing for tissue-specific tropism.
- Microfluidic Mixing
Precise control over the self-assembly process ensures highly monodisperse nanoparticles with consistent N/P (nitrogen-to-phosphate) ratios.
- TFF-Mediated Purification
Utilizing high-performance tangential flow filtration (TFF) for rapid buffer exchange and concentration, minimizing lipid hydrolysis, and maintaining particle integrity.
- Advanced Thermal Analysis
Integration of freeze-drying microscopy (FDM) and modulated DSC to establish the thermodynamic boundaries required for long-term solid-state stability.
- Ligand-Mediated Targeting
Expert conjugation of GalNAc, peptides, or antibodies to the nanoparticle surface for receptor-mediated uptake in extrahepatic tissues.
The Strategic Bypass. For Better Bioavailability.
Our service portfolio encompasses a suite of RNA delivery solutions, spanning a wide range of modalities and administration routes. The cornerstone of our offering is the development of LNPs, the gold standard for mRNA delivery, which feature fully customizable compositions of ionizable lipids, helper lipids, and PEG-lipids. We further engineer polymer-based systems for specialized release kinetics, create hybrid nano-formulations that combine the advantages of lipids and polymers, and perform oligonucleotide conjugations for targeted delivery. For novel solutions, we provide custom lipid synthesis to meet specific biological or intellectual property needs. Beyond parenteral delivery, we pioneer non-traditional routes: our oral solid dose service develops protective matrices utilizing pH-responsive polymers and permeation enhancers to make oral RNA delivery a viable option for chronic treatments; our rectal dosage service designs thermosensitive gels and suppositories to leverage unique venous drainage and bypass first-pass metabolism. We also provide non-sterile liquid formulations, such as stable suspensions and emulsions optimized for pediatric or geriatric use, and sterile liquid formulations for injections, meticulously adjusted for physiological compatibility. Finally, to overcome cold-chain limitations, our lyophilized drug formulation service converts RNA-LNPs into stable, room-temperature-storable dry powders that maintain full bioactivity upon reconstitution.
Oral Solid Dose Formulation Development Service
While traditionally challenging for nucleic acids, we develop protective matrices that shield RNA from the acidic gastric environment and enzymatic degradation in the small intestine. Our approach utilizes pH-responsive polymers and intestinal permeation enhancers to facilitate mucosal uptake, making oral RNA delivery a viable reality for chronic treatments.
Rectal Dosage Formulation Development Service
This service exploits the unique venous drainage of the rectum to bypass first-pass metabolism. We design thermosensitive in situ gelling systems and lipid-based suppositories that ensure stable, localized, or systemic delivery of RNA, offering a crucial alternative for patients who cannot tolerate parenteral or oral routes.
Non-sterile Liquid Dose Formulation Development Service
Focused on preclinical research and oral liquid applications, this service provides high-stability suspensions and emulsions. We optimize flavor profiles and viscosity for pediatric or geriatric applications, ensuring that the RNA-LNP complexes remain dispersed and bioactive without the need for immediate refrigeration.
Sterile Liquid Formulation Development Service
Our sterile liquid service is tailored for IV, IM, or SC injections. We focus on achieving physiological compatibility through meticulous pH and tonicity adjustment while preventing LNP aggregation. We utilize advanced aseptic processing and container-closure integrity testing to meet the most stringent regulatory standards for parenteral products.
Lyophilized Drug Formulation Development Service
To eliminate the need for ultracold chain logistics, we convert liquid RNA-LNPs into stable dry powders. By utilizing specific lyoprotectants and optimized cooling rates, we preserve the secondary structure of the RNA and the morphological integrity of the nanoparticle, ensuring rapid reconstitution and full bioactivity after months of storage at room temperature.
Workflow
Molecular Profiling & In Silico Design
We initiate the process with molecular profiling of the RNA payload. This involves computational analysis of its secondary structure, base composition, and pKa to predict potential interactions with various lipid components and buffer systems. This in silico screening allows for the rational design of initial LNP compositions that are more likely to ensure RNA stability, efficient encapsulation, and successful delivery, thereby de-risking the early experimental stages.
LNP Library Screening
Leveraging high-throughput automated platforms, we generate a diverse library of small-scale LNP formulations. This library systematically explores the combinatorial space of ionizable lipids, cholesterol, PEG-lipids, and helper lipids (e.g., DSPC). The goal is to rapidly identify lead candidates that exhibit optimal characteristics for encapsulation efficiency, particle size, and stability, providing a strong foundation for further development.
Process Optimization
A critical phase involves the meticulous refinement of microfluidic mixing parameters. We systematically optimize key variables such as total flow rate (TFR), flow rate ratio (FRR), and total lipid concentration. This precise control over the self-assembly process is essential for consistently achieving the target particle size (typically 70-100 nm), a low polydispersity index (PDI), and high RNA encapsulation efficiency (>90%).
Physicochemical Characterization
Each LNP batch undergoes a rigorous battery of analytical tests. This includes dynamic light scattering (DLS) for measuring hydrodynamic diameter and PDI, electrophoretic light scattering for zeta potential determination, and analytical techniques such as capillary electrophoresis (CE) or Ribogreen assay to confirm RNA integrity and quantify encapsulation efficiency. This dataset ensures the LNPs meet predefined CQAs.
Accelerated Stability & Stress Testing
Lead formulations are subjected to accelerated stability studies and stress testing under various conditions, including thermal stress, mechanical shear, and different pH levels. These studies are vital for identifying the most robust storage conditions (e.g., frozen vs. refrigerated) and for selecting primary packaging components that maintain LNP stability and functionality over time.
Scale-Up & Documentation
The final step involves the seamless transition of the optimized process from microfluidic screening to pilot-scale manufacturing. We establish a robust, scalable process and compile a comprehensive chemistry, manufacturing, and controls (CMC) data package.
Publication Data
Journal: Signal Transduction and Targeted Therapy
DOI: 10.1038/s41392-024-02002-z
Published: 2024
Results: The authors provide a comprehensive review of the progress and future potential of mRNA-based therapeutics, with a primary focus on linear non-replicating mRNA. The review systematically details the preclinical and clinical applications of mRNA drugs, categorizing them into immunotherapies (e.g., vaccines for infectious diseases, cancer, and autoimmune disorders) and non-immunotherapies (e.g., protein replacement, regenerative medicine, genome editing). A central theme is the dual role of mRNA immunogenicity, which is beneficial for vaccines but undesirable for protein-replacement therapies, necessitating different design strategies. The authors emphasize that individual patient factors, such as age, gender, and underlying health conditions, critically influence the efficacy and safety of mRNA treatments, highlighting the need for personalized approaches. The review also discusses the pivotal role of advanced delivery systems, particularly lipid nanoparticles (LNPs), in the success of mRNA drugs. Finally, the authors analyze the current challenges, including stability, delivery efficiency, and potential adverse effects, and outline future research directions to overcome these hurdles and expand the clinical utility of mRNA technology.
Applications
Prophylactic Vaccines
Our RNA-LNP platforms provide the rapid response and high immunogenicity required for next-generation vaccines against viral and bacterial pathogens, ensuring robust T-cell and B-cell responses in various patient populations.
Oncology Immunotherapy
We develop specialized formulations for cancer vaccines that deliver tumor-associated antigens to dendritic cells. Our systemic reprogramming strategies can turn "cold" tumors "hot," enhancing the efficacy of existing immune checkpoint inhibitors.
Rare Genetic Disorders
For diseases caused by protein deficiencies, our mRNA delivery systems enable the sustained intracellular production of therapeutic proteins, offering a potentially curative approach for conditions that currently have no effective treatments.
RNA Interference (RNAi)
We optimize siRNA delivery for the targeted silencing of disease-causing genes in the liver and beyond, providing a high-potency solution for metabolic disorders and cardiovascular diseases with minimal off-target effects.
Advantages
Exceptional Encapsulation Efficiency
Our microfluidic platforms consistently achieve over 95% encapsulation efficiency for various RNA payloads. This ensures that the majority of your high-value API is protected and delivered, reducing overall dose requirements and cost of goods.
Precision Tissue Targeting
By modifying the LNP surface with specific ligands or adjusting the lipid composition, we can achieve extrahepatic delivery to the lungs, spleen, and bone marrow. This overcomes the natural tendency of nanoparticles to accumulate exclusively in the liver.
Superior Shelf Stability
Our lyophilization expertise allows for the storage of RNA-LNP products at 4°C or room temperature for extended periods. Published data confirms that our formulations maintain >90% mRNA integrity and potency for over 24 weeks under refrigerated conditions.
Scalable Manufacturing Solutions
We utilize "limit-size" characterization to ensure that the critical quality attributes identified at the bench scale are perfectly replicated during large-scale manufacturing. This minimizes the risk of batch failure during the transition to clinical production.
Frequently Asked Questions
Customer Review
CD BioGlyco solved a major stability hurdle for our siRNA candidate. Their lyophilization protocol allowed us to ship our product globally without dry ice, a massive win for our clinical logistics.
— By Dr. A.J., Senior Director, Pharmaceutical Sciences
The encapsulation efficiency we achieved with CD BioGlyco was significantly higher than what we had seen with other providers. This directly translates to a lower dose and a better safety profile in our NHPs.
— By Manager K.T., R&D Department
CD BioGlyco's rapid turnaround time allowed us to test five different LNP compositions in just six weeks. This speed was essential for our competitive position in the mRNA vaccine space.
— By Principal Scientist E.G., Vaccine Development
Associated Services
To provide a holistic approach to precision drug delivery, we offer specialized RNA delivery platforms:
Optimized for rapid conjugation of targeting ligands in aqueous environments for high-throughput screening.
Utilizing solid-support chemistry for precise, high-purity synthesis of complex RNA conjugates.
Integrating GalNAc-lipids directly into the nanoparticle bilayer for enhanced hepatocyte uptake.
Employing bio-orthogonal click chemistry for modular and efficient attachment of targeting moieties to nanoparticles.
CD BioGlyco is committed to accelerating the future of medicine by solving the most complex challenges in RNA delivery. Our world-class facilities and expert scientific team are ready to partner with you to bring your RNA-based drug candidate to life. Whether you are in the early stages of discovery or preparing for clinical trials, our formulation development service provides the precision and reliability your project deserves. Please contact us.
Reference
- Shi, Y.; et al. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduction and Targeted Therapy. 2024, 9(1): 322. (Open Access)